
Alnylam Pharmaceuticals ALNY
$ 328.75
-1.25%
Annual report 2025
added 02-12-2026
Alnylam Pharmaceuticals Gross Profit 2011-2026 | ALNY
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit Alnylam Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 195 M | 73.1 M | - | - | - | - | - | - | 82.8 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 195 M | 73.1 M | 117 M |
Gross Profit of other stocks in the Biotechnology industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
180 M | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
1.27 M | - | 2.71 % | $ 14 M | ||
|
Cabaletta Bio
CABA
|
0.006 | $ 3.34 | 0.45 % | $ 3.9 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.52 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
102 K | - | -10.17 % | $ 12.2 K | ||
|
Codexis
CDXS
|
52.8 M | $ 1.02 | 1.49 % | $ 74.9 M | ||
|
Cerus Corporation
CERS
|
60.4 M | $ 2.6 | 1.37 % | $ 480 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-428 K | - | -18.52 % | $ 27.3 M | ||
|
Cellectis S.A.
CLLS
|
37.7 M | $ 3.87 | -0.39 % | $ 116 M | ||
|
Acorda Therapeutics
ACOR
|
119 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-32.3 K | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
2.32 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
774 M | - | - | - | ||
|
AIkido Pharma
AIKI
|
10 K | - | 1.93 % | $ 17.4 M | ||
|
Collegium Pharmaceutical
COLL
|
128 M | $ 41.75 | 0.19 % | $ 1.32 B | ||
|
Albireo Pharma
ALBO
|
39.2 M | - | -0.23 % | $ 916 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
301 M | $ 36.14 | 1.23 % | $ 3.75 B | ||
|
Amarin Corporation plc
AMRN
|
166 M | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
Catalyst Pharmaceuticals
CPRX
|
87.5 M | $ 23.77 | 2.99 % | $ 2.91 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
3.94 M | $ 8.41 | -1.87 % | $ 36.4 M | ||
|
Cardiff Oncology
CRDF
|
245 K | $ 1.94 | 0.01 % | $ 130 M | ||
|
Curis
CRIS
|
9.5 M | $ 1.1 | -3.51 % | $ 6.94 M | ||
|
Aeterna Zentaris
AEZS
|
4.73 M | - | 5.93 % | $ 314 M | ||
|
CorMedix
CRMD
|
61.7 K | $ 7.16 | 0.42 % | $ 364 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-523 K | - | -11.43 % | $ 502 K | ||
|
Champions Oncology
CSBR
|
12.8 M | $ 6.14 | 3.89 % | $ 83.9 M | ||
|
Aravive
ARAV
|
5.68 K | - | -13.39 % | $ 1.45 M | ||
|
Aptinyx
APTX
|
1.56 K | - | -39.0 % | $ 4.57 M | ||
|
Aridis Pharmaceuticals
ARDS
|
1 K | - | 17.91 % | $ 11.1 M | ||
|
Altimmune
ALT
|
8.18 K | $ 4.21 | -2.32 % | $ 299 M | ||
|
CEL-SCI Corporation
CVM
|
255 K | $ 3.88 | -8.92 % | $ 247 M |